Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSIPL: Biologics and Sublingual Immunotherapy in HDM-driven Asthma
NCT06027073Phase 4Not yet recruiting
- Sponsor
- Medical University of Silesia
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Allergy Immunotherapy
01
Overview
A Phase 4 trial of omalizumab, House dust mite allergen extract in allergic asthma, sponsored by Medical University of Silesia. Planned start May 2024; status: not yet recruiting.
02
Drugs
omalizumabHouse dust mite allergen extract
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT06027073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027073.